drugset / Trial / NCT01603446

L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome

NCT01603446

Phase 2 Completed 7 enrolled The Hospital for Sick Children
Non-randomizedParallel-groupOpen-labelTreatment

Summary

MELAS patients suffer from exercise intolerance, weakness, poor vision or blindness, poor growth, developmental delay, and deafness. They also have unique 'stroke-like' episodes (SLEs) which are not due to blockages of large or medium arteries. These 'strokes' are thought to be due to energy failure of very small brain blood vessels combined with energy failure in the mitochondria (cell battery) of the brain cells, especially in the back region of the brain in the vision centre. This leads to visual loss and paralysis. The overall goal of this study is to better understand the mechanism of these SLEs at the level of the brain cells and small blood vessels.

Timeline

Start
2012-05
Primary completion
2013-05
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject L-arginine Small molecule 100 mg/kg Oral

Indications